THE QATAR CARDIOVASCULAR BIOREPOSITORY (QCBIO)

DESIGN AND PROGRESS TO DATE

2013 Mayo Foundation for Medical Education and Research

Progress

Enrolled patients

1673

patient enrolled into study

Registered patients

1673

registered patients

Incomplete survey

3

patients with incomplete surveys

Attached Document
Consent Form
Download
Attached Document
NPRP Approval
Download
Attached Document
Progress Report
Download
Attached Document
Amendment Approval Notice
Download

Abstract

Background

Coronary heart disease (CHD) poses a major health burden in the Gulf countries. Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care. We describe design of a biorepository with linkage to medical records to facilitate discovery of biomarkers for CHD.

Methods

The goal of the Qatar Cardiovascular Biorepository (QCBio) is to archive plasma and DNA of 1000 Qatari patients with CHD and 1000 age, gender and ethnicity-matched controls who have no history of CHD. Cases will include patients needing percutaneous intervention for symptomatic CHD or admitted with an acute coronary syndrome (myocardial infarction or unstable angina). Controls will be identified from the blood bank as adults who have no history of CHD. Relevant risk factors and comorbid conditions will be ascertained by electronic medical record (EMR)-based electronic phenotyping algorithms that include diagnosis and procedure codes, medication use, and laboratory data. We will include processes to promote use of the biorepository by Qatar investigators by facilitating access to the repository for biomarker research, while maintaining the highest ethical standards with emphases on patient confidentiality and stewardship of the biospecimens.

Results

Thus far, we have:

  • Created a patient questionnaire in Arabic to obtain information on demographic factors, cardiovascular disease risk factors, and family history;
  • Hired the technologist for sample processing, aliquoting, and DNA extraction;
  • Hired and trained the study coordinators who will recruit patients;
  • Developed consent forms in Arabic.

We have obtained approval from the Hamad Medical Center IRB. Equipment and infrastructure is now in place and recruitment has begun. We will put in place a Laboratory Information Management System (LIMS) for sample tracking, set up a website for the study, and will present at various seminars and conferences of the Cardiovascular Department to increase awareness of QCBio.

Objectives

1. Archive plasma and DNA of 1000 Qatari patients with CHD and 1000 age-, gender-, and ethnicity-matched controls who have no history of CHD. 2. Ascertain relevant risk factors and comorbid conditions by electronic medical record (EMR)-based electronic phenotyping algorithms that include diagnosis and procedure codes, medication use, and laboratory data. 3. Include processes to promote use of the biorepository by Qatar investigators by facilitating access to the repository for biomarker research, while maintaining the highest ethical standards with emphases on patient confidentiality and stewardship of the biospecimens.

Methods

Cases will include patients needing percutaneous intervention for symptomatic CHD or admitted with an acute coronary syndrome (myocardial infarction or unstable angina).

  • Controls will be identified from the blood bank as adults who have no history of CHD.
  • Relevant risk factors and comorbid conditions will be ascertained by electronic medical record (EMR)-based electronic phenotyping algorithms that included diagnosis and procedure codes, medication use and laboratory data.
  • DNA will be extracted from lymphocytes.
  • Plasma and serum will be stored at -80°.


Pattern of recruitment for the Vascular Disease Biorepository. EMR 1⁄4 electronic medical record.

Survey

Attached survey form for this research.

Attached Document
Survey Form
Download

Results

Thus far, we have

  • a) Developed consent forms in Arabic. b) Created a patient questionnaire in Arabic to obtain information on demographic factors, cardiovascular disease risk factors, and family history; c) Hired the technologist for sample processing, aliquoting, and DNA extraction; and d) Hired and trained the study coordinators who will recruit patients
  • We have also obtained approval from the Hamad Medical Center IRB.
  • Equipment and infrastructure is now in place and recruitment has begun.
  • We have put in place a Laboratory Information Management System (LIMS) for sample tracking.
  • Set up a website for the study to increase awareness of QCBio.

Consent Form

1. Consent form is in Arabic
2. Consent obtained by research assistants
3. Participants consent to allowing DNA or tissue to be kept for future research, which might include studies done by researchers not at the Hamad Medical Corporation
4. Participants acknowledge that they are not expected to benefit directly

Overview of the Vascular Disease Biorepository. RLIMS 1⁄4 research laboratory information management systems; CAS 1⁄4 carotid artery stenosis; AAA 1⁄4 abdominal aortic aneurysm; PAD 1⁄4 peripheral arterial disease.

Discussion

Coronary heart disease (CHD) poses a major health burden in the Gulf countries. Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care. We describe design of a biorepository with linkage to medical records to facilitate discovery of biomarkers for CHD.

Conclusion

A biorepository of 1000 CHD cases and 1000 controls in Qatar (QCBio) will enable future investigation of genomic and proteomic biomarkers for early detection and prognostication and to identify new targets for drug development.